BioGaia AB (publ) (STO:BIOG.B)
Sweden
· Delayed Price · Currency is SEK 109.60
-0.70 (-0.63%)
At close: Mar 9, 2026
BioGaia AB Revenue
In the year 2025, BioGaia AB had annual revenue of 1.54B SEK with 8.11% growth. BioGaia AB had revenue of 440.57M in the quarter ending December 31, 2025, with 20.76% growth.
Revenue
1.54B
Revenue Growth
+8.11%
P/S Ratio
7.25
Revenue / Employee
6.36M
Employees
242
Market Cap
11.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.54B | 115.45M | 8.11% |
| Dec 31, 2024 | 1.42B | 126.21M | 9.73% |
| Dec 31, 2023 | 1.30B | 192.55M | 17.44% |
| Dec 31, 2022 | 1.10B | 318.85M | 40.61% |
| Dec 31, 2021 | 785.11M | 38.03M | 5.09% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cereno Scientific AB | 44.27M |
| EQL Pharma AB | 425.75M |
| Swedish Orphan Biovitrum AB | 28.24B |
| Orexo AB | 26.00M |
| Cinclus Pharma Holding AB | 57.47M |
| Nanexa AB | 55.94M |
| Dicot Pharma AB | 200.00K |
| Enzymatica AB | 53.90M |